Citations

Clear

16280 citation(s) found for "Yu, David".

Pathological staging predicts survival more accurately than clinical staging in locally advanced rectal cancer following total neoadjuvant therapy
Ng, Jyi Cheng , Sassun, Richard , Sileo, Annaclara , Perry, William , Mathis, Kellie L. , Larson, David W. , Larson, David W , Cheng, Jyi Ng , Perry, William R , Sassun, Richard

Mayo Clinic

British Journal of Surgery | March 11, 2025 | Volume: 112 | Issue: 3 | Pages: No page available

10.1093/bjs/znaf034 | PMID 40067085 Get It

Definitions, diagnosis, and management of postoperative recurrence in Crohn’s disease patients with permanent ileostomy—a systematic review and meta-analysis
Abushamma, Suha , Yadete, Tesfaye , Nero, Neil , Falloon, Katherine , Parker, Claire E. , Ahuja, Vineet, Armuzzi, Alessandro , Bemelman, Willem A. , Bruining, David H. , Feagan, Brian G. , Hart, Ailsa, Leong, Rupert W. , Narula, Neeraj , Raine, Tim , Singh, Siddharth , Sparrow, Miles , Spinelli, Antonino , Koughnett, Julie Ann Van, Solitano, Virginia , Yuan, Yuhong , Rieder, Florian , Deepak, Parakkal , Dignass, Axel , Fulmer, Clifton , Halfvarson, Jonas , Holubar, Stefan D , Ma, C , Magro, F , McCurdy, Jeffrey D , Narula, Neeraj , Panes, Julian , Raine, Tim , Regueiro, Miguel , Spinelli, Antonino , Rieder, Florian , Solitano, Virginia , Leong, Rupert W , Abreu, María T. , Ahuja, Vineet , Deepak, Parakkal , Dotan, Iris , Fulmer, Clifton G. , Hart, Ailsa , Holubar, Stefan D. , Ma, Christopher , Magro, Fernando , Panés, Julián , Regueiro, Miguel , Rogler, Gerhard , Vuyyuru, Sudheer K. , Jairath, Vipul

Mayo Clinic

Journal of Crohn's and Colitis | March 11, 2025 | Volume: 19 | Issue: 4 | Pages: No page available

10.1093/ecco-jcc/jjaf041 | PMID 40066499 Get It

Abstract Background and Aims Over 10% of patients with Crohn’s disease require permanent ileostomy. We aimed to summarize the existing data on diagnosis, definitions of recurrence, and management of Crohn’s disease patients with permanent ileostomy. Methods MEDLINE, Embase, and CENTRAL databases were searched from inception to February 6, 2024. Randomized controlled trials, cohort and cross-sectional studies, and case series of more than 5 patients reporting on postoperative recurrence or the need for surgery in patients with Crohn’s disease and permanent ileostomy were included. Search results were independently screened, and full text of all titles meeting eligibility criteria was obtained. Outcomes of interest included diagnostic techniques, recurrence definitions, and management approaches. We estimated pooled rates (with 95% confidence interval [CI]) of recurrence. Results Thirty cohort studies including 2055 Crohn’s patients with permanent ileostomy were included (53% female, median age at the time of ileostomy creation 32 years, the most common reason for ileostomy was refractory disease). The postoperative recurrence rate was 27% (95% CI, 21.3–33.3, 26 studies, 451/1805 patients). Modalities for diagnosis of Crohn’s disease recurrence were symptoms (15 studies), endoscopy (4 studies), histology from endoscopic biopsies (2 studies), imaging (5 studies), and surgery (22 studies). The reported definitions of recurrence for each modality were heterogeneous. Conclusions There is a lack of standardized monitoring tools and criteria for diagnosing recurrence in patients with Crohn’s disease and permanent ileostomy. The results of this systematic review will form the basis of a global expert recommendation exercise focused on developing management standards and trial endpoints for this condition.
Determinants of late metastases in renal cell carcinoma
Kapur, Payal , Zhong, Hua , Christie, Alana , Xu, Haitao , Cai, Qi , Araj, Ellen, Kim, David , Miyata, Jeffrey , Tcheuyap, Vanina Toffessi , Ball, Colleen T. , Thiel, David D. , Parker, Alexander S. , Antwi, Samuel O. , Leibovich, Bradley C. , Cheville, John C. , Tcheuyap, Vanina T , Leibovich, Bradley C , Modrusan, Zora , Brugarolas, James , Antwi, Samuel O , Kapur, Payal , Kim, David , Modrušan, Zora , Brugarolas, James

Mayo Clinic

JNCI: Journal of the National Cancer Institute | March 11, 2025 | Volume: 117 | Issue: 7 | Pages: 1387-1400

10.1093/jnci/djaf060 | PMID 40065697 Get It

Abstract Background The mechanisms underlying metastatic latency in renal cell carcinoma (RCC) remain poorly understood. Methods This study evaluated 2 large independent cohorts for differences in tumor biology between patients who developed metastases early (≤1 year after nephrectomy) and those with late onset (>3 years). Results In the discovery cohort (n = 161), late metastatic RCC was associated with clear cell histology (88.9% vs 78.7%), lower pathological stage (pT1-2; 40.3% vs 18.0%), and favorable histopathological features including low grade (40.0% vs 2.3%), less sarcomatoid (5.6% vs 21.8%), and reduced necrosis (37.7% vs 78.3%; all P < .02). Late metastatic RCC tumors exhibited increased angiogenesis (63.5% vs 19.4%) and reduced inflammation (78.8% vs 50.0%; all P < .02) profiles. Genomic driver analyses revealed comparable rates of PBRM1 and SETD2 loss in late and early metastatic RCC, while BAP1 loss was significantly less common in late metastatic RCC (7.5% vs 27.1%; P < .02). In multivariable models, BAP1/PBRM1/SETD2 status and tumor necrosis emerged as key discriminators of late metastatic RCCs. These findings were confirmed in the second cohort (n = 307). Late metastatic RCC was enriched for fatty acid oxidation and angiogenesis pathways, supporting a less aggressive phenotype. This was further evidenced by a lower engraftment rate in murine models (0% vs 36.5%; P < .001) and significantly longer overall survival from the time of metastasis (median survival doubled, P < .001). Interestingly, late metastatic RCC shared genomic and phenotypic features with RCC that metastasizes to the pancreas, suggesting a common underlying biology influencing both metastatic latency and pancreatic tropism. Conclusions Overall, these findings advocate for recognition of late metastatic RCC because of its distinct biology and improved prognosis.
Choice of Anesthetic for Laparoscopic Bariatric Surgery Can Reduce the Use of Rescue Antiemetics in Postanesthesia Recovery Room: A Retrospective Observational Study
Šprung, Juraj , Ghanem, Omar M. , Lu, Lauren , Salame, Marita , Schroeder, Darrell R., Schroeder, Darrell R. , Lu, Lauren Y, Sprung, J , Schroeder, Darrell , Warner, David O. , Weingarten, Toby N.

Mayo Clinic

Surgical Laparoscopy, Endoscopy & Percutaneous Techniques | March 10, 2025 | Volume: 35 | Issue: 2 | Pages: No page available

10.1097/sle.0000000000001341 | PMID 40063267 Get It

Objective: Postoperative nausea and vomiting (PONV) is a frequent adverse event after bariatric surgery and is associated with patient dissatisfaction and increased health care burden. Aggressive multimodal antiemetic prophylaxis and the use of propofol infusion during anesthesia are associated with the reduction of PONV. In this study, we examined the use of rescue antiemetics following bariatric surgery performed with 3 different anesthetic strategies designed to reduce PONV: (1) primary volatile (VOL) anesthetic and propofol (PROP) infusion (VOL+PROP), (2) volatile anesthetic with propofol and dexmedetomidine (DEX) infusions (VOL+PROP+DEX), or (3) opioid-sparing total intravenous anesthesia (PROP+DEX). Methods: In this retrospective observational study, we included patients undergoing bariatric surgery from 2018-2022 who received 1 of 3 anesthetics: (1) VOL+PROP, (2) VOL+PROP+DEX, or (3) opioid-sparing PROP+DEX without a VOL. Inverse probability of treatment weighting analysis determined the association between the need for rescue-antiemetics in the postanesthesia care unit (PACU) and following PACU discharge. Results: Three hundred thirty-two patients received VOL+PROP, 354 VOL+PROP+DEX, and 166 PROP+DEX, and all received prophylactic antiemetics during surgery. After surgery, the PROP+DEX patients received fewer rescue antiemetics in the PACU compared with VOL+PROP (11% vs. 24%, P=0.002), and VOL+PROP+DEX fewer compared with VOL+PROP (16% vs. 24%, P=0.023). This differential antinausea effect was limited to PACU stay only. Rescue antiemetic use increased across all anesthetic management groups following PACU discharge until midnight on the day of surgery (ranging from 38% to 46% across groups, P=0.71) and through the first postoperative day (ranging from 47% to 57% across groups, P=0.20). Conclusions: The benefit associated with anesthetic strategies designed to reduce PONV was present but did not persist past PACU discharge. This finding suggests that aggressive perioperative multimodal antiemetic prophylaxis combined with anesthetic strategies designed to prevent PONV after bariatric surgery have only a short-lived effect, thus health care staff in hospital wards may expect to encounter high rates of PONV in these patients. There is a need for the development of novel antinausea treatments to reduce the rate of this frequent postoperative complication.
Proceedings of the 29th Annual Congress of the International Liver Transplantation Society
Patel, Madhukar S. , Tejedor, Marta , Barbas, Andrew S. , Kim, Joohyun , Shingina, Alexandra , Wilson, Elizabeth A. , Alconchel, Felipe , Patel, Dhupal , Liu, Jiang , Mazzola, Alessandra, Tanaka, Tomohiro , Victor, David W. , Yoon, Young-in, Vinaixa, Carmen , Kyaw, Aye Mya Mya , Galante, Antonio, Kathirvel, Manikandan , Moral, Kenan , Maira, Tommaso Di , Martin, Eléonora De , Mao, Shennen, Tejedor, Marta , Wilson, Elizabeth , Alconchel, Felipe , Di Maira, Tommaso , Shankar, Sadhana , Mao, Shennen A. , Ivanics, Tommy , Mathew, Johns Shaji , Khan, Mohammad Qasim , Syn, Nicholas L. X. , Nasralla, David , Mazzola, Alessandra , Yoon, Young-in, Magistri, Paolo , Aliseda, Daniel , Chadha, Ryan , Bonaccorsi‐Riani, Eliano , Rammohan, Ashwin , Patel, Madhukar

Mayo Clinic

Liver Transplantation | March 10, 2025 | Volume: 31 | Issue: 7 | Pages: 945-955

10.1097/lvt.0000000000000593 | PMID 40062745 Get It

The 2024 Annual Congress of the International Liver Transplantation Society (ILTS) was from May 1–4 in Houston, Texas, USA, under the theme “Liver Disease and Transplantation: Breaking Barriers and Exploring New Frontiers.” In addition to a robust scientific program, the congress also hosted a hands-on cadaveric robotic liver surgery course, a machine perfusion workshop, and a transesophageal echocardiography course. In this report, the ILTS Vanguard and Basic Sciences Committees present a summary of the congress proceedings.
Real‐World Outcomes of Relapsed/Refractory Core‐Binding Factor Acute Myeloid Leukemia: A COMMAND Registry Study
Rojek, Alexandra E. , McCormick, Benjamin J. , Odetola, Oluwatobi , Abaza, Yasmin , Nai, Nhi , Foucar, Charles , Achar, Rohan K. , Shallis, Rory M. , Bradshaw, Danielle , Standridge, Meaghan, Badar, Talha , Patel, Anand , Abaza, Yasmin , Nai, Nhi , Kota, Vamsi , Badar, Talha , Patel, Anand , Rojek, Alexandra E , Cwykiel, Joanna M. , Kota, Vamsi , Murthy, Guru Subramanian Guru

Mayo Clinic

American Journal of Hematology | March 10, 2025 | Volume: 100 | Issue: 6 | Pages: 1082-1085

10.1002/ajh.27664 | PMID 40062542 Get It

Why do people still make anti‐D over 50 years after the introduction of Rho(D) immune globulin? A Biomedical Excellence for Safer Transfusion (BEST) Collaborative study
DelBaugh, Regina M. , Murphy, Michael , Staves, Julie , Fachini, Roberta , Hands, Katie , Bub, Carolina Bonet , Cohn, Claudia S. , Cox, Cody A., Ziman, Alyssa , Fermon, Erica J., Peters, Jessica, Collaborative, BEST foRmation of Anti‐D After Rhogam (RADAR) Study Investigators and the Biomedical Excellence for Safer Transfusion (BEST), Callum, Jeannie , Murphy, Michael , Wendel, Silvano , Bonet-Bub, Carolina , Cohn, Claudia S , Jacquot, Cyril , Hasan, Rida A , Lu, Wen , Juskewitch, Justin E , Raval, Jay S , Fung, Mark K , Ziman, Alyssa , Dunbar, Nancy M , Kutner, José Mauro , Cox, Cody A., Jacquot, Cyril , Hasan, Rida A. , Lu, Wen , Juskewitch, Justin E. , Raval, Jay S. , Rollins‐Raval, Marian A. , Gorlin, Jed B. , Dunbar, Nancy M. , Collaborative, BEST foRmation of Anti‐D After Rhogam (RADAR) Study Investigators and the Biomedical Excellence for Safer Transfusion (BEST)

Mayo Clinic

Transfusion | March 10, 2025 | Volume: 65 | Issue: 5 | Pages: 957-967

10.1111/trf.18202 | PMID 40059673 Get It

Abstract Background Rho(D) immune globulin (RhIg) is used to reduce RhD alloimmunization in pregnancy. This study describes potential causes for RhD alloimmunization after the development and implementation of RhIg. Study Design and Methods This retrospective descriptive study investigated RhD‐negative patients born in 1965–2005 with anti‐D newly identified during 2018–2022. Transfusion, pregnancy, intravenous drug abuse, and transplantation were considered potential alloimmunization sources. Results There were 1200 study patients (852 females; 348 males) at 30 institutions in 5 countries (USA, Canada, UK, New Zealand, Brazil). Most patients had a single potential source of alloimmunization identified (857/1200, 71%), most commonly pregnancy among females (537/852, 63%) and transfusion among males (180/348, 52%). When multiple potential sources were included, males were more likely than females to have a history of transfusion (235/348 [68%] vs. 149/852 [17%], p < .0001) and confirmed or suspected intravenous drug abuse (100/348 [29%] vs. 138/852 [16%], p < .0001). Among females with a history of pregnancy, 119/718 (17%) had healthcare access issues, 120/718 (17%) had pregnancy in a country where they may not have received RhIg, and 21/718 (3%) refused RhIg. Among patients with a history of transfusion, males were more likely than females to have received RhD‐positive red blood cells or whole blood (143/235 [61%] vs. 30/149 [20%], p < .0001) and/or platelets (84/235 [36%] vs. 19/149 [13%], p < .0001). Discussion Pregnancy was the most frequently identified potential source of RhD alloimmunization among females. Transfusion was most frequent in males. Intravenous drug abuse as a common potential source among patients with RhD alloimmunization merits further study.
Letter: Effect of Aqueous Tears on Topical Fluorescein Tracer Emission Signal from Cornea and Anterior Chamber
Kishi, Alyson , Bryant, Alana D., Reed, David M. , Toris, Carol B. , Gulati, Vikas , Sit, Arthur J. , Fan, Shan , Kazemi, Arash , Moroi, Sayoko E. , Kazemi, Arash A, Moroi, Sayoko E , Sit, Arthur J

Mayo Clinic

Journal of Ocular Pharmacology and Therapeutics | March 10, 2025 | Volume: 41 | Issue: 4 | Pages: 226-227

10.1089/jop.2024.0143 | PMID 40063350 Get It

A Multi-Institutional Analysis of Device Failures in a Recent Cochlear Implant Series
Freeman, M.H. , Lindquist, Nathan R. , Dornhoffer, James R. , Siddiqui, Taimur , Saoji, Aniket A. , Kutz, Walter, Sweeney, Alex D. , Haynes, David S. , Carlson, Matthew L., Bennett, Marc , Freeman, Michael H , Yancey, Kristen L. , Patro, Ankita , Lovin, Benjamin D. , Holder, Jourdan Taylor , Carlson, Matthew L.

Mayo Clinic

Otology & Neurotology | March 10, 2025 | Volume: 46 | Issue: 7 | Pages: 789-795

10.1097/mao.0000000000004438 | PMID 40062369 Get It

Objective To assess Advanced Bionics (AB) HiRes Ultra and Ultra 3D initial version (V1) cochlear implant electrode failures over time at four large cochlear implant programs. Study Design Retrospective cohort. Setting Four tertiary referral centers. Patients Patients receiving AB HiRes Ultra and Ultra 3D initial version (V1) devices as of December 31, 2022. Main Outcome Measures Failure rate, revision surgery, speech recognition scores. Results Over a span of 7 years, 205 (42.6%) of 483 implanted V1 devices have failed. Device failure rate varied across institutions from 32 to 67%. Of the 205 detected failures, 163 (79%) have undergone revision surgery, with 94% of revisions being performed with Advanced Bionics devices. Average time from implantation to diagnosis of device failure was 2.7 ± 1.2 years. Most patients (89.8%) with available testing were matched or exceeded their best prefailure speech performance after implant revision. After revision, patients had an average CNC score improvement of 24.7 percentage points over their most recent pre-revision scores and demonstrated average datalogging of 12.7 ± 4.1 h/d at most recent evaluation. Conclusions Comparison of patients across multiple high-volume implant centers confirms the presence of ongoing device failures. There is variability across institutions in the rate of revision surgery once a patient is diagnosed with a V1 device failure, as well as in the rate of device failure detection. Inter-institutional variability in failure rates may be explained by the variation in the routine use of electrical field imaging. Reimplantation with a new device typically results in a return to prefailure peak performance. Professional Practice Gap & Educational Need To our knowledge, a comparison of AB HiRes (V1) device failures across multiple institutions has not been conducted. Learning Objective To identify device failure rate across multiple institutions with different testing protocols. Desired Result Providers will have an improved understanding of the trajectory of device failures for HiRes (V1) devices over time. Level of Evidence Level IV—Historical cohort or case-controlled studies. Indicate IRB or IACUC IRB #230017; IRB #22-000183; IRB #STU-032018-085; IRB #H-49479.
Effect of erenumab versus other migraine preventive medications on cardiovascular and cerebrovascular outcomes: A United States claims database‐based observational cohort study
Dodick, David W. , Tepper, Stewart J. , Khodavirdi, Ani C., Pannacciulli, Nico, Fu, Alan , Kent, Shia T. , Gill, Karminder, Urman, Robert , Dodick, David W , Ailani, Jessica , Oh, Sam S.

Mayo Clinic

Headache: The Journal of Head and Face Pain | March 7, 2025 | Volume: 65 | Issue: 6 | Pages: 919-932

10.1111/head.14912 | PMID 40033803 Get It

Abstract Objective To estimate the real‐world risk of cardiovascular events among patients with migraine treated with erenumab and other migraine preventive medications. Background Migraine preventive treatment with calcitonin gene‐related peptide (CGRP) pathway inhibitors, such as erenumab and others, may theoretically result in cardiovascular effects due to a lack of compensatory vasodilation with CGRP pathway inhibition. Methods In this retrospective observational cohort study, we estimated the unadjusted cumulative risk (CR) of new‐onset hypertension, acute myocardial infarction (MI), or stroke among patients with migraine newly treated with erenumab, other anti‐CGRP pathway monoclonal antibodies (mAbs), standard oral preventive medications, and onabotulinumtoxinA using data from the MarketScan® Commercial and Medicare Supplemental medical claims database. Comparative analyses to assess the relative risk (RR) of vascular events were gated on the comparability of treatment groups with respect to baseline demographics and clinical characteristics. Potential bias due to unmeasured confounding was evaluated via negative control outcome (NCO) analyses. Confounding based on measured covariates and differential informative censoring were addressed with inverse probability weights. Results A total of 108,019 new users of migraine preventive medications were included. Unadjusted CR (95% confidence interval [CI]) of hypertension at 12 months of treatment was: erenumab, 9.34% (8.79–9.89%); other anti‐CGRP pathway mAbs, 9.42% (8.92–9.92%); standard oral preventive medications, 9.09% (8.77–9.41%); and onabotulinumtoxinA, 9.10% (8.39–9.81%). NCO analyses identified minimal concerns related to unmeasured confounding in erenumab versus other mAbs and erenumab versus onabotulinumtoxinA comparisons. Adjusted RRs (95% CIs) of acute MI and stroke, respectively, at 36 months of treatment were 1.02 (0.45–1.59) and 0.90 (0.56–1.25) for erenumab versus other mAbs and 0.87 (0.19–1.55) and 0.97 (0.42–1.52) for erenumab versus onabotulinumtoxinA. Conclusions In this analysis of the MarketScan medical claims database, we found no difference in the risk of vascular events in patients treated with erenumab versus other anti‐CGRP pathway mAbs or onabotulinumtoxinA.